Everything below concerns Cyclic AMP. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-03-21. Where a claim depends on a specific study, the study is described rather than over-claimed.
Two forms circulate in research settings and are frequently confused. One carries the drug affinity complex and is often written as CJC-1295 with DAC; the other lacks that group and is usually called modified GRF(1-29). The two share the same core sequence but differ sharply in how long they persist in blood. Products labelled only as CJC-1295 normally refer to the version carrying the complex. Documentation that omits the distinction leaves the intended molecule ambiguous.
CJC-1295 is a synthetic peptide built as a long-acting analogue of growth hormone-releasing hormone. Its backbone matches the first twenty-nine residues of the natural human hormone, with four amino acid substitutions added to slow enzymatic breakdown. A reactive maleimide group, commonly termed the drug affinity complex, allows the peptide to attach to circulating albumin after administration. That albumin attachment keeps the molecule in the bloodstream for an extended period instead of being cleared within minutes.
Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.
Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C152H252N44O42 | Cited for the form without the drug affinity complex |
| Molecular weight | About 3368 Da | Reported value for modified GRF(1-29) |
| Appearance | White to off-white powder | Lyophilised solid as usually supplied |
| Solubility | Soluble in water and polar solvents | Clarity depends on purity and salt content |
| Typical storage | -20 C or below, dry | Protect from light and repeated warming cycles |
Four amino acid substitutions separate the modified backbone from the parent GRF(1-29) sequence. These changes reduce recognition by dipeptidyl peptidase IV and related proteases, extending the interval before degradation. Development work in this area sought longer-acting GHRH analogs for endocrine investigation. Published descriptions treat the substitution set as a defining property of the core sequence, while the albumin-binding linker is described separately as an optional addition to that same backbone.
CJC-1295 is a synthetic peptide analog of growth hormone-releasing hormone, constructed on the 29-amino-acid fragment designated GRF(1-29). The name began as an internal development code during the 1990s and later spread through research supply catalogs and discussion forums. The molecule does not occur in nature; its sequence is engineered rather than isolated from tissue. Two related compounds are sold under this single label, and they differ by one appended chemical group that strongly influences how long the peptide remains in circulation.
The dividing feature between the two forms is a maleimide-based drug affinity complex, abbreviated DAC. In the DAC-bearing version, a linker attaches the peptide to serum albumin after administration, and that association slows removal from plasma. The version lacking DAC appears in catalogs as MOD GRF(1-29) or tetrasubstituted GRF(1-29). Because informal writing treats both as one item, comparisons drawn from such sources routinely blend measurements taken from two molecules with substantially different behavior.
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
Batch-to-batch consistency depends on solid-phase peptide synthesis and subsequent purification. Coupling efficiency, resin choice, and cleavage conditions all affect the final profile. Counter-ion content and moisture can shift the apparent mass of a batch. Documentation typically includes a certificate of analysis with chromatograms and spectra. Independent verification by a second laboratory is sometimes requested. Whether a given certificate reflects the actual vial contents depends on chain of custody. Analytical methods themselves carry uncertainty that should be stated alongside results.
Lyophilized material is typically stored at minus twenty degrees Celsius or lower. Keeping the vial dry and protected from light preserves peptide integrity. Repeated freeze-thaw cycles can cause aggregation or loss of activity. Once dissolved, solutions are generally kept at two to eight degrees Celsius. Stability data for reconstituted solutions vary, and long-term behavior is not fully established. Working aliquots reduce the number of times a stock container is opened.
Reverse-phase high-performance liquid chromatography is the standard tool for purity assessment. The technique separates the target peptide from truncated or modified byproducts. Mass spectrometry confirms molecular weight and supports sequence verification. Electrospray ionization and matrix-assisted laser desorption are both used. Amino acid analysis provides an independent check on composition. Purity values are commonly reported as area percentage from the chromatogram. Residual trifluoroacetate and water content are also measured in many quality programs.
Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
In 2019, NCCD became the knowledge partner for the International Solar Alliance to help foster solar energy used in cold chains in its UN member countries. Through NCCD, various myths about India's cold storage sector were rectified and it brought about a paradigm shift in policies. NCCD was awarded the Agribusiness Leadership Award in India in 2014. In 2018, in recognition of the individual contributions of then CEO of NCCD, the University of Birmingham conferred him the title of honorary Professor. Through five technical committees constituted under NCCD, various domain experts within the country are also able to contribute in the works undertaken by NCCD. These include training in cold chain operations, workshops to encourage policy level interface between decision makers in government and operators, as well as knowledge dissemination through capacity building and awareness programmes. NCCD is recognized as the nodal body for cold chain development in India and for its unique construct, as an ecosystem of public and private sector stakeholders that serves to provide the country context relevant direction for its initiatives to develop cold chain for its agricultural sector.
) which are the radial, tangential and longitudinal dimensions respectively, in inches, with the longitudinal dimension divided by ten because water diffuses about 10 times more rapidly in the longitudinal direction (along the grain) than in the lateral dimensions. The solution to the above equation is:
After the first two days the insurgents lost their offensive initiative, and the combined South African forces drove PLAN back across the border in a counteroffensive codenamed Operation Merlyn. Between 1 and 9 April 1989, 273 PLAN insurgents were killed in the fighting. The SADF and police suffered 23 dead. On 8 April 1989, the JMMC issued the Mount Etjo Declaration, which reiterated that the Tripartite Accord was still in effect and that South Africa, Angola, and Cuba remained committed to peace. It also ordered all PLAN insurgents remaining in Ovamboland to surrender at UNTAG-supervised assembly points. Sam Nujoma denied any incursion had taken place on 1 April, claiming that he had only ordered PLAN insurgents already inside South West Africa to begin establishing base camps. He also pointed out that SWAPO had never been a signatory to the Tripartite Accord, and therefore the cessation of hostilities as dictated by its terms was non-binding. This drew some ire from Angola, which had given guarantees to the UN that PLAN would remain north of the 16th parallel. The SADF was re-confined to its bases on 26 April, then released into Ovamboland again to verify that the insurgents had departed. By May, all but a small handful of PLAN insurgents had been relocated north of the 16th parallel under JMMC supervision, effectively ending the South African Border War. General elections under a universal franchise were held in South West Africa between 7 and 11 November 1989, returning 57% of the popular vote for SWAPO.
nuclear pore A complex of membrane proteins that creates an opening in the nuclear envelope through which certain molecules and ions are permitted to pass and thereby enter or exit the nucleus (analogous to the channel proteins in the cell membrane). The nuclear envelope typically has thousands of pores to selectively regulate the exchange of specific materials between the nucleoplasm and the cytoplasm, including messenger RNAs, which are transcribed in the nucleus but must be translated in the cytoplasm, as well as nuclear proteins, which are synthesized in the cytoplasm but must return to the nucleus to serve their functions.
=== Chemical analyses === Blotting paper is used in chemical analyses as stationary phase in thin-layer chromatography. Blotting paper is also used in pool/spa maintenance to measure pH balance. Small squares of blotting paper attached to disposable plastic strips are impregnated with pH sensitive compounds usually extracted from lichens, especially Roccella tinctoria. These strips are used similarly to litmus strips, however filter paper is usually used for litmus strips, generally to allow for the property of diffusion.
Sources: en.wikipedia.org
In chemistry, a hypercycle is an abstract model of organization of self-replicating molecules connected in a cyclic, autocatalytic manner. It was introduced in an ordinary differential equation (ODE) form by the Nobel Prize in Chemistry winner Manfred Eigen in 1967 and subsequently further extended in collaboration with Peter Schuster. It was proposed as a solution to the error threshold problem encountered during modelling of replicative molecules that hypothetically existed on the primordial Earth (see: abiogenesis). As such, it explained how life on Earth could have begun using only relatively short genetic sequences, which in theory were too short to store all essential information. The hypercycle is a special case of the replicator equation. The most important properties of hypercycles are autocatalytic growth competition between cycles, once-for-ever selective behaviour, utilization of small selective advantage, rapid evolvability, increased information capacity, and selection against parasitic branches.
IGC experiments are typically carried out at "infinite dilution", where only small amounts of probe molecule are injected. This region is also called Henry's law region or linear region of the sorption isotherm. At infinite dilution probe-probe interactions are assumed negligible and any retention is only due to probe-solid interactions. The resulting retention volume, VRo, is given by the following equation:
== Etymology and meaning == The English word mummy is derived from medieval Latin Mumia, a borrowing of the medieval Arabic word mūmiya (مومياء) which meant an embalmed corpse, as well as the bituminous embalming substance. This word was borrowed from Persian where it meant asphalt, and is derived from the word mūm meaning wax. The meaning of "corpse preserved by desiccation" developed post-medievally. The Medieval English term "mummy" was defined as "medical preparation of the substance of mummies", rather than the entire corpse, with Richard Hakluyt in 1599 AD complaining that "these dead bodies are the Mummy which the Phisistians and Apothecaries doe against our willes make us to swallow". These substances were called mummia. The Oxford English Dictionary defines a mummy as "the body of a human being or animal embalmed (according to the ancient Egyptian or some analogous method) as a preparation for burial", citing sources from 1615 AD onward. However, Chamber's Cyclopædia and the Victorian zoologist Francis Trevelyan Buckland define a mummy as follows: "A human or animal body desiccated by exposure to sun or air. Also applied to the frozen carcase of an animal imbedded in prehistoric snow". Wasps of the genus Aleiodes are known as "mummy wasps" because they wrap their caterpillar prey as "mummies".
Another bill allowed developers to build housing on some lots previously zoned exclusively for commercial use without getting local governments' permission if a certain percentage of the housing was affordable. A third bill allowed for the construction of market-rate housing on some lots previously zoned exclusively for commercial use. At the signing ceremony for the latter two bills, Newsom warned local governments, which have a history of blocking and delaying housing developments, that they would be held accountable for future housing obstructionism. Other bills he signed required localities "to approve or deny various building permits within a strict timeline" and streamlined student and faculty housing projects by allowing California colleges to skip onerous review processes for new projects. Measures and actions to reduce homelessness in California have not yet solved the problem. The number of homeless reached a record 181,000 in January 2023. According to some, to cope with this problem, California must build more than 2.5 million housing units.
== Pharmacology == 4-HT is a potent agonist of the serotonin 5-HT2A receptor similarly to psilocin (EC50Tooltip half-maximal effective concentration = 38 nM and 21 nM, respectively). It also shows affinity for the serotonin 5-HT2C receptor (Ki = 40 nM), the serotonin 5-HT1A receptor (Ki = 95 nM), and the serotonin 5-HT1B receptor (Ki = 1,050 nM). The drug produces serotonergic peripheral effects in animals, shows similar metabolism and metabolic stability to psilocin, and appears to cross the blood–brain barrier and hence is centrally penetrant. Surprisingly however, the compound, similarly to baeocystin, norbaeocystin, and norpsilocin, does not produce the head-twitch response, a behavioral proxy of psychedelic effects, in animals, and hence is putatively non-hallucinogenic. In older literature, the psychoactive effects of 4-hydroxylated tryptamines have been said to increase in the series of 4-hydroxytryptamine, 4-hydroxy-N-methyltryptamine (norpsilocin], and 4-hydroxy-N,N-dimethyltryptamine (psilocin). The reason for the lack of hallucinogenic effects with 4-HT and related compounds is unknown, but may be due to biased agonism of the serotonin 5-HT2A receptor; or, more specifically, biased agonism for the β-arrestin2 signaling pathway. Norbaeocystin is thought to be a prodrug of 4-HT, analogously to how psilocybin is a prodrug of psilocin and how baeocystin is thought to be a prodrug of norpsilocin.
Sources: en.wikipedia.org
It is a synthetic peptide analogue of growth hormone-releasing hormone. Four substitutions in its sequence make it more resistant to enzymatic degradation than the natural hormone. In the version carrying a drug affinity complex, the peptide binds albumin and remains in circulation for days.
No regulatory agency has approved CJC-1295 for clinical use. Human trials were conducted in the 2000s, but the development programme was discontinued before any marketing application succeeded. Material sold today is offered as a research chemical, and its purity depends on the supplier.
Sermorelin is an unmodified fragment of growth hormone-releasing hormone and is cleared quickly. CJC-1295 contains substitutions that resist breakdown, and the form with a drug affinity complex persists much longer. Both act at the same receptor but differ substantially in duration of action.
It acts on the growth hormone-releasing hormone receptor found on pituitary somatotroph cells. Activation of that receptor triggers growth hormone release through a cyclic AMP dependent pathway.